Who
Cynthia Louise Flowers
Director
Company insider
Files Form 4 as: Director, Lisata Therapeutics; Director, G1 Therapeutics; Director, Kadmon Holdings.
In numbers
- Trades disclosed
- 39
- Buys
- 2
- Sells
- 0
- Bought
- $127K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Jun 2018
- Last trade
- 9 Jan 2026
- Last filed
- 13 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,789 at $0.00 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeutics | SEC FORM 4 Code D | —20,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeutics | SEC FORM 4 Code U | —15,889 | filing |
| 13 Jun 2024filed 14 Jun 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 Jan 2024filed 11 Jan 2024 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —19,480 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 Jan 2023filed 11 Jan 2023 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jan 2022filed 12 Jan 2022 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,430 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $469K64,935 at $7.23 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $721K100,000 at $7.21 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $430K85,034 at $5.06 | filing |
News
No headline names them, or the companies they trade most, lately.